Synonym
AVE-9488; AVE 9488; AVE9488;
IUPAC/Chemical Name
2,2-Difluoro-benzo[1,3]dioxole-5-carboxylic acid indan-2-ylamide
InChi Key
OKCJNSDIVCXYAL-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H13F2NO3/c18-17(19)22-14-6-5-12(9-15(14)23-17)16(21)20-13-7-10-3-1-2-4-11(10)8-13/h1-6,9,13H,7-8H2,(H,20,21)
SMILES Code
O=C(C1=CC=C(OC(F)(F)O2)C2=C1)NC3CC4=C(C=CC=C4)C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
317.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Luna M, Karavitakis M. Treating portal hypertension in cirrhotic rats with AVE 9488. Liver Int. 2009 Oct;29(9):1448; author reply 1448-9. doi: 10.1111/j.1478-3231.2009.02093.x. Epub 2009 Jul 31. PubMed PMID: 19659506.
2: Frantz S, Adamek A, Fraccarollo D, Tillmanns J, Widder JD, Dienesch C, Schäfer A, Podolskaya A, Held M, Ruetten H, Ertl G, Bauersachs J. The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury. Basic Res Cardiol. 2009 Nov;104(6):773-9. doi: 10.1007/s00395-009-0041-3. Epub 2009 Jun 23. PubMed PMID: 19548059.
3: Schäfer A, Fraccarollo D, Widder J, Eigenthaler M, Ertl G, Bauersachs J. Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer. Eur J Heart Fail. 2009 Apr;11(4):336-41. doi: 10.1093/eurjhf/hfp005. Epub 2009 Feb 3. PubMed PMID: 19193626.
4: Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation. 2008 Aug 19;118(8):818-27. doi: 10.1161/CIRCULATIONAHA.107.717702. Epub 2008 Aug 4. PubMed PMID: 18678774.
5: Biecker E, Trebicka J, Kang A, Hennenberg M, Sauerbruch T, Heller J. Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Liver Int. 2008 Mar;28(3):331-8. doi: 10.1111/j.1478-3231.2008.01664.x. PubMed PMID: 18290775.
6: Bauersachs J, Widder JD. Endothelial dysfunction in heart failure. Pharmacol Rep. 2008 Jan-Feb;60(1):119-26. Review. PubMed PMID: 18276993.
7: Wohlfart P, Xu H, Endlich A, Habermeier A, Closs EI, Hübschle T, Mang C, Strobel H, Suzuki T, Kleinert H, Förstermann U, Ruetten H, Li H. Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther. 2008 May;325(2):370-9. doi: 10.1124/jpet.107.128009. Epub 2008 Feb 5. PubMed PMID: 18252813.
